Price movement over the last 24 hours
ADMA Biologics Inc vs Dominion Energy Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Dominion Energy Inc trades at $69.92 (market cap $60.92B). The key difference: Dominion Energy Inc is far larger — about 28.6× ADMA Biologics Inc's market cap, and Dominion Energy Inc pays a 3.86% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | D | |
|---|---|---|
Market Cap | $2.13B | $60.92B |
Sector | Health | Utilities |
52-Week High | $20.38 | $69.84 |
52-Week Low | $7.60 | $56.32 |
Enterprise Value | $2.20B | $113.32B |
Dividend Yield | — | 3.86% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Dominion Energy (D) trades at $69.84, up 0.13% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 16.93% net income margin and trades near the analyst consensus price target of $69.50. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning Dominion as a key player in AI infrastructure and data center power demand.
The outlook remains positive due to strategic positioning in renewable energy and data center growth, though regulatory approval risks for the merger and high debt levels pose challenges. Earnings momentum and institutional support provide upside potential, but investors should monitor merger developments and interest rate impacts on utility valuations.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →